Clinical trial · Interventional
Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer
Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial The goal of this clinical trial is to find out if adding consolidation chemotherapy with capecitabine after total neoadjuvant chemoradiotherapy (TNT) works to improve oncologic outcomes in patients with stage I rectal cancer. It will also comparethe safety of adding consolidation chemotherapy before local excision. The main questions it aims to answer are: * Does adding consolidation chemotherapy increase the rate of pathologic complete response? * What medical problems or side effects do participants have during and after treatment? Researchers will compare TNT followed by local excision to TNT followed by consolidation chemotherapy with capecitabine and then local excision to see if adding consolidation chemotherapy improves tumor response and treatment outcomes. Participants will: * Receive TNT for stage I rectal cancer * Be randomly assigned to one of two treatment groups * Undergo local excision after preoperative treatment * Visit the clinic for checkups and tests to evaluate tumor response, side effects, recurrence, survival, quality of life, bowel function, urinary function, sexual function, circulating tumor DNA, and treatment-related costs
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Capecitabine | — | UNRESOLVED | — |
| Consolidation Therapy | — | UNRESOLVED | — |
| Organ Preservation | — | UNRESOLVED | — |
| Rectal Cancer Stage I | Malignant Rectal Neoplasm | CURATED_BROADER | 0.78 |
| Total Neoadjuvant Treatment | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TNT followed by local excision | Drug | — | UNRESOLVED |
| TNT with additional consolidation chemotherapy followed by local excision | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- TNT with consolidation therapy
- interventionNames
- Drug: TNT with additional consolidation chemotherapy followed by local excision
- type
- ACTIVE_COMPARATOR
- label
- TNT without consolidation therapy
- interventionNames
- Drug: TNT followed by local excision
Primary outcomes (1)
- measure
- Pathologic complete response rate (ypT0)
- timeFrame
- At pathologic assessment of the local excision specimen, approximately 10 weeks after completion of TNT
- description
- Pathologic complete response of the primary tumor after neoadjuvant therapy
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed rectall adenocarcinoma * Low rectal cancer (AV \< 15cm) * cT2N0 disease, or pathologic stage T1N0 disease after endoscopic resection with at least one high-risk feature, including: Positive resection margin Lymphovascular invasion Tumor budding ≥5 * Ability to understand and comply with the requirements of the clinical trial Exclusion Criteria: * Patients who prefer radical rectal resection * Prior history of surgery for rectal cancer * Recurrent rectal cancer * Synchronous metastatic rectal cancer * Evidence of lymph node metastasis or distant metastasis on abdominopelvic CT or chest CT, including para-aortic, common iliac, or external iliac lymph node metastasis * Uncontrolled active infection or other uncontrolled medical condition * Known hypersensitivity to chemotherapy * Patients considered unsuitable for participation in the clinical trial by the principal investigator or study personnel
References
Publications (0)
Data not yet available